Which tumor types require lurbinectedin readministration?

Which tumor types have documented benefit from lurbinectedin readministration?

The provided information does not include any tumor-type–specific evidence or labeling details about when lurbinectedin readministration is recommended. Without that source material, it is not possible to name the tumor types that require readministration.

Where to verify the exact tumor types (labeling, trial protocols, and payer guidance)

To identify which tumor types require readministration, you would typically check:
- The lurbinectedin prescribing information (including sections on “Dosage and Administration,” “Dose Modifications,” and any retreatment/readministration language).
- Clinical trial inclusion criteria or retreatment rules for specific cancers.
- Treatment guidelines and payer policies that reference the formal readministration criteria.

If you share the specific document(s) or excerpt you are using (for example, the label text or a guideline page), I can extract the tumor types exactly as written.

If you paste the readministration criteria, I can map them to tumor types

If you paste the relevant part that mentions “readministration” (or “re-administration,” “retreatment,” “beyond progression,” etc.), I can return a clean list of the tumor types tied to those criteria.